Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer

C. Sessa; M. D'Incalci; I. Valente

Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer

C. Sessa, M. D'Incalci, I. Valente

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.

Original language	English
Pages (from-to)	1233-1234
Number of pages	2
Journal	Cancer Treatment Reports
Volume	66
Issue number	5
Publication status	Published - 1982

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

@article{dc01bea7c4214d999508b1987fec4ffa,

title = "Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer",

abstract = "This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.",

author = "C. Sessa and M. D'Incalci and I. Valente",

year = "1982",

language = "English",

volume = "66",

pages = "1233--1234",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "5",

}

TY - JOUR

T1 - Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer

AU - Sessa, C.

AU - D'Incalci, M.

AU - Valente, I.

PY - 1982

Y1 - 1982

N2 - This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.

AB - This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020332695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020332695&partnerID=8YFLogxK

M3 - Article

C2 - 6805951

AN - SCOPUS:0020332695

VL - 66

SP - 1233

EP - 1234

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 5

ER -

Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this